Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

GlaxoSmithKline UK
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 17/07/2008
SPC Zinnat Tablets 125mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/07/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   03-Jul-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.4 - Amendment to paragraph on 'prolonged use cefuroxime axeti'

Section 4.8 - Amendment to infections and infestations - removal of 'from prolonged use'

Section 10 - Added the date of approval
Updated on 07/08/2007 and displayed until 17/07/2008
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Amendment to list of excipients.
Updated on 15/02/2007 and displayed until 07/08/2007
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   01/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

For further information, please contact GlaxoSmithKline on +44 (0)800 221 441
Updated on 09/05/2006 and displayed until 15/02/2007
Reasons for adding or updating:
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 (date of (partial) revision of the text
Date of revision of text on the SPC:   27/04/06
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

For further information, please contact GlaxoSmithKline on +44 (0)800 221 441
Updated on 31/10/2005 and displayed until 09/05/2006
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 17/06/2003 and displayed until 31/10/2005
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 6. 5 - Nature and Contents of Container
Updated on 10/03/2003 and displayed until 17/06/2003
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 09/07/2002 and displayed until 10/03/2003
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
Updated on 30/05/2002 and displayed until 09/07/2002
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 20/08/2001 and displayed until 30/05/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 22/05/2002 and displayed until 20/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 12/07/2000 and displayed until 22/05/2002
Reasons for adding or updating:
  • No reasons supplied
Updated on 15/05/2000 and displayed until 12/07/2000
Reasons for adding or updating:
  • No reasons supplied
Updated on 12/04/2000 and displayed until 15/05/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  cefuroxime